SAINTE-FOY, QUEBEC--(Marketwire - April 29, 2008) - Bioxel Pharma Inc. (TSX VENTURE: BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs,, today announced the departure of Pascal Delmas as President and Chief Executive Officer and as a Board member, as well as the appointment of Thomas Warden as Vice-President, Sales, Marketing and Regulatory Affairs. The departure of Mr. Delmas will be effective as of May 30, while the appointment of Mr. Warden is effective as of today.
